(Correcting) misdiagnoses of asthma: a cost effectiveness analysis

BMC Pulmonary Medicine

Shawn Aaron²  Katherine Vandemheen²  Douglas Coyle³  Amanda Sumner¹  Smita Pakhale² 

[1] Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, ON K1H 8L1, Canada;University of Ottawa, and The Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada;Department of Epidemiology and Community Medicine, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5 Canada

关键词: epidemiology of asthma;    economic analysis;    asthma secondary screening;    asthma cost savings;    Canadian asthma cost;    Asthma cost;   

Others  :  1172550
DOI  :  10.1186/1471-2466-11-27

 received in 2010-11-09, accepted in 2011-05-23,  发布年份 2011

【 摘 要 】

Background

The prevalence of physician-diagnosed-asthma has risen over the past three decades and misdiagnosis of asthma is potentially common. Objective: to determine whether a secondary-screening-program to establish a correct diagnosis of asthma in those who report a physician diagnosis of asthma is cost effective.

Method

Randomly selected physician-diagnosed-asthmatic subjects from 8 Canadian cities were studied with an extensive diagnostic algorithm to rule-in, or rule-out, a correct diagnosis of asthma. Subjects in whom the diagnosis of asthma was excluded were followed up for 6-months and data on asthma medications and heath care utilization was obtained. Economic analysis was performed to estimate the incremental lifetime costs associated with secondary screening of previously diagnosed asthmatic subjects. Analysis was from the perspective of the Canadian healthcare system and is reported in Canadian dollars.

Results

Of 540 randomly selected patients with physician diagnosed asthma 150 (28%; 95%CI 19-37%) did not have asthma when objectively studied. 71% of these misdiagnosed patients were on some asthma medications. Incorporating the incremental cost of secondary-screening for the diagnosis of asthma, we found that the average cost savings per 100 individuals screened was $35,141 (95%CI $4,588-$69,278).

Conclusion

Cost savings primarily resulted from lifetime costs of medication use averted in those who had been misdiagnosed.

【 授权许可】

   
2011 Pakhale et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 1.

Figure 3.

【 参考文献 】

• [1]National Asthma Survey[http://www.cdc.gov/nchs/about/major/slaits/nas.htm] webcite 2007.
• [2]Statistics Canada: Persons with asthma, by age and sex. [http://www40.statcan.gc.ca/l01/cst01/health49a-eng.htm?sdi=asthma] webcite 2009.
• [3]Sharpe HM, Sin DD, Andrews EM, Cowie RL, Man P: Alberta Strategy to Help Manage Asthma (ASTHMA): a provincial initiative to improve outcomes for individuals with asthma. Healthc Q 2004, 7(3):55-60. 4
• [4]Jin R, Choi BC, Chan BT, McRae L, Li F, Cicutto L, et al.: Physician asthma management practices in Canada. Can Respir J 2000, 7(6):456-465.
• [5]O'Dowd LC, Fife D, Tenhave T, Panettieri RA: Attitudes of physicians toward objective measures of airway function in asthma. Am J Med 2003, 114(5):391-396.
• [6]Diaz-Lobato S, Mayoralas S: Underuse of Spirometry in Primary Care. Chest 2004, 126(5):1712-1713.
• [7]Aaron SD, Vandemheen KL, Boulet LP, McIvor RA, Fitzgerald JM, Hernandez P, et al.: Overdiagnosis of asthma in obese and nonobese adults. Can Med Assoc J 2008, 179(11):1121-1131.
• [8]McKnight-Eily L, Elam-Evans L, Strine T, Zack M, Perry G, Presley-Cantrell L, et al.: Activity limitation, chronic disease, and comorbid serious psychological distress in U.S. adults ΓÇô BRFSS 2007. International Journal of Public Health 2009, 54(0):111-119.
• [9]Kamble S, Bharmal M: Incremental Direct Expenditure of Treating Asthma in the United States. Journal of Asthma 2009, 46(1):73-80.
• [10]Krahn MD, Berka C, Langlois P, Detsky AS: Direct and indirect costs of asthma in Canada, 1990. Can Med Assoc J 1996, 154(6):821-831.
• [11]Schedule of Benefits for Physician Services, edited on June 2008 [http:/ / www.health.gov.on.ca/ english/ providers/ program/ ohip/ sob/ physserv/ physserv_mn.html] webcite
• [12]Ontario Drug Benefit Formulary/Comparative Drug Index: Ministry of Health and Long-term Care of Ontario 2009. Ministry of Health and Long-term Care of Ontario; 2009.
• [13]Corrigan SP, Cecillon DL, Sin DD, Sharpe HM, Andrews EM, Cowie RL, et al.: The costs of implementing the 1999 Canadian Asthma Consensus Guidelines recommendation of asthma education and spirometry for the family physician. Can Respir J 2004, 11(5):349-353.
• [14]Campbell MK, Togerson DJ: Bootstrapping: estimating confidence intervals for cost-effectiveness ratios. QJM 1999, 92:177-182.
• [15]Luks VP, Vandemheen KL, Aaron SD: Confirmation of asthma in an Era of Overdiagnosis. Eur Respir J 2010, 09031936.
• [16]Cisternas MG, Blanc PD, Yen IH, Katz PP, Earnest G, Eisner MD, et al.: A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003, 111(6):1212-1218.
• [17]Weiss KB, Gergen PJ, Hodgson TA: An economic evaluation of asthma in the United States. N Engl J Med 1992, 326(13):862-866.
• [18]Bahadori K, Doyle-Waters M, Marra C, Lynd L, Alasaly K, Swiston J, et al.: Economic burden of asthma: a systematic review. BMC Pulmonary Medicine 2009, 9(1):24. BioMed Central Full Text
• [19]Kenny P, Lancsar E, Hall J, King M, Chaplin M: The individual and health sector costs of asthma: the first year of a longitudinal study in New South Wales. Aust N Z J Public Health 2005, 29(5):429-435.
• [20]Ungar WJ, Coyte PC, Chapman KR, MacKeigan L: The patient level cost of asthma in adults in south central Ontario. Pharmacy Medication Monitoring Program Advisory Board. Can Respir J 1998, 5(6):463-471.
• [21]Awadh BN, Grunfeld A, Fitzgerald JM: Health care costs associated with acute asthma: a prospective economic analysis. Can Respir J 1999, 6(6):521-525.
• [22]Haynes RB, Sackett DL, Taylor DW, Gibson ES, Johnson AL: Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med 1978, 299(14):741-744.